Real-world Study of Incadronate in Breast Cancer Patients With Metastatic Bone Disease: clinIcal Efficacy and Safety
This is a real-world study to explore the efficacy and safety of incadronate in the treatment of breast cancer patients with bone metastases.
• Male or female aged 18 years or above;
• Can understand the purpose of clinical trials and the benefits and risks, voluntarily participate in and sign the informed consent
• The physical status score of the Eastern Cooperative Oncology Group (ECOG) was ≤3;
• Histologically or cytologically confirmed breast cancer;
• Imaging or histocytology confirmed bone metastases;
• There were indications of useing Incadronate and no contraindications in the use of Incadronate;
• New York Heart Association（NYHA）cardiac function grade ≤II, No serious heart disease;
• All women of childbearing age, fertile men or their spouses did not plan to have children or donate sperm throughout the trial period until 6 months after the last dose, or voluntarily took effective contraceptive measures.